Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Payables: 2020-2025

Historic Payables for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $3.8 million.

  • Caribou Biosciences' Payables rose 40.68% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year decrease of 10.64%. This contributed to the annual value of $2.5 million for FY2024, which is 20.64% down from last year.
  • According to the latest figures from Q3 2025, Caribou Biosciences' Payables is $3.8 million, which was up 17.30% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Payables ranged from a high of $5.9 million in Q1 2024 and a low of $426,000 during Q2 2022.
  • Over the past 3 years, Caribou Biosciences' median Payables value was $3.2 million (recorded in 2024), while the average stood at $3.4 million.
  • Per our database at Business Quant, Caribou Biosciences' Payables tumbled by 89.43% in 2022 and then surged by 940.61% in 2023.
  • Caribou Biosciences' Payables (Quarterly) stood at $4.0 million in 2021, then slumped by 71.28% to $1.1 million in 2022, then surged by 172.25% to $3.1 million in 2023, then fell by 20.64% to $2.5 million in 2024, then skyrocketed by 40.68% to $3.8 million in 2025.
  • Its Payables stands at $3.8 million for Q3 2025, versus $3.2 million for Q2 2025 and $3.9 million for Q1 2025.